Cangene submits hyperimmune globulin NDS

Cangene (TSE:CNJ) submitted an NDS for Canadian approval of its anti-hepatitis B hyperimmmune globulin therapy to treat patients exposed to hepatitis B virus (HBV). The product also is under review in...